ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Sun profit surges on U.S. generic cancer drug,Cipla profit slumps

MUMBAI (NewsRise) -- Sun Pharmaceutical Industries, India's largest drug maker, reported a quarterly profit that beat analysts' estimates, aided by its exclusive launch of a generic cancer drug in the U.S., but smaller rival Cipla said net income nearly halved from last year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more